Buffalo Round Table - November 10, 2018
Antibody Drug Conjugates As Immunotherapy In Myeloma
Racial Disparities in Multiple Myeloma
New Drug for Myeloma Targeting Myeloma Cell Survival Pathway
Can Comedy Help Cure Cancer? Spellchek Features HealthTree on a Viral Video.
Creating Your Most Valuable Plan (MVP) in Multiple Myeloma with David Winfield and Don Baylor Jr.
We interviewed Dave Winfield & Don Baylor Jr. to share how Don Baylor handled the highs & lows of myeloma & the importance of creating your Most Valuable Plan.
What is Neutropenia? What Does it Mean to Myeloma Patients?
What is Stem Cell Collection and How Long Does it Take?
The Myeloma Crowd Launches HealthTree® Aimed at Accelerating a Cure for Multiple Myeloma
Clinical Trial: Phase II Antibody Drug Conjugate Trial for Relapsed/Refractory Myeloma Patients
Engineered Toxin Bodies (EBTs), a New Treatment Approach for Multiple Myeloma
Scottsdale Round Table - October 14, 2018
New Jersey: Hackensack Meridian Health's New Myeloma Institute
The Three Most Common Genes for African American Multiple Myeloma Patients
Higher Risk of MGUS in Immediate Family Members with Multiple Myeloma
Stem Cell Transplant as a Multiple Myeloma Immunotherapy
Stating the Obvious: Having Drug Insurance Coverage Improves Outcomes for Myeloma Medicare Patients
MRD Test by Adaptive (clonoSEQ) Gains FDA Approval in Multiple Myeloma
Racial Disparities in Multiple Myeloma with Ashraf Badros, MD, University of Maryland
Dr. Badros shares his insights and research of multiple myeloma for the black community
Obesity in Myeloma: Abdominal Fat Better than BMI to Predict Multiple Myeloma
CAR T Therapy Update by Edward Stadtmauer, MD, University of Pennsylvania
Swimming As Exercise: Have You Tried It?
Putting One Foot In Front of the Other: Why Multiple Myeloma Patient Paula Waller Chooses to Keep Moving
In Memory of Multiple Myeloma Patient John Runyon
